© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
June 11, 2021
Oncologist Susan Miesfeldt, MD, of MaineHealth, discussed the importance of genetic testing and counseling for breast and ovarian cancers as well as barriers that must be addressed in order to reach more patients eligible for these services.
June 07, 2021
Margetuximab, trastuzumab deruxtecan, and tucatinib have all been approved in the past 2 years for the treatment of various subsets of patients with breast cancer.
June 04, 2021
Research has also shown activity with sacituzumab govitecan in subsets of patients with triple-negative breast cancer, such as those with active brain metastases.
June 03, 2021
Study suggests that 8 out of 10 patients with breast cancer who receive treatment with TARGIT-IORT will not need a long course of post-operative external beam radiotherapy.
June 02, 2021
Rates of death among patients with breast cancer due to any cause were 31% higher in states with Medicaid income eligibility limits no greater than 50% of the federal poverty level.
May 25, 2021
Breast cancer patients with low or absent MLH1 or PMS2 gene expression may have even greater risks of death.
This discovery could enhance efforts to develop better treatments for breast, ovarian, and prostate cancer.
May 24, 2021
The study authors sought to examine the risks of subsequent primary cancers (SPCs) among breast cancer survivors by HR status and age at diagnosis.
May 17, 2021
The findings contrast with those for adult BMI, which indicate that women who gain weight after menopause have an increased risk of postmenopausal breast cancer.
May 14, 2021
As breast cancer becomes an increasingly treatable disease, clinicians should provide personalized follow-up care to address varying burdens of symptoms up to 5 years after diagnosis.